The NeurologyLive® Migraine Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with migraine disorders.
Raising Cranial Neuralgias Awareness via Improved Diagnostics: Paul G. Mathew, MD, DNBPAS, FAAN, FAHSJuly 29th 2021
The assistant professor of neurology at Harvard Medical School provided thoughts on the need to increase awareness on cranial neuralgias and the importance of the diagnostic process for this condition.
NeuroVoices: Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, on Intricacies in Treating Posttraumatic Headache and Associated NeuralgiasJuly 28th 2021
The assistant professor of neurology at Harvard Medical School detailed his recent review involving the diagnosis and management of posttraumatic headache with associated cranial neuralgias.
Researching Posttraumatic Headache With Cranial Neuralgias: Paul G. Mathew, MD, DNBPAS, FAAN, FAHSJuly 27th 2021
The assistant professor of neurology at Harvard Medical School discussed the motivation behind uncovering more about painful cranial neuralgias and their association with posttraumatic headache.
NeuroVoices: Aarushi Suneja, MD, and Zubair Ahmed, MD, on Improving Migraine Treatment OptimizationJuly 21st 2021
The duo from Cleveland Clinic stressed the reasons for conducting real-world data assessing migraine treatments and why it can lead to the ultimate goal of treatment optimization.
Improving Use of Telemedicine in Minority Communities: Aarushi Suneja, MD; Zubair Ahmed, MDJuly 4th 2021
The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.
Study Comparing Rimegepant and Galcanezumab for Migraine Prevention AnnouncedJune 29th 2021
Patients will be randomized to either 120-mg galcanezumab or 75-mg rimegepant and will be evaluated on the percentage of patients achieving a 50% reduction in monthly migraine headache days.
NeuroVoices: Aarushi Suneja, MD, and Zubair Ahmed, MD, on Knowledge Gaps With COVID-19 HeadachesJune 23rd 2021
The duo from Cleveland Clinic addressed several of their research projects presented at AHS 2021 that covered a range of COVID-19 related topics, including the unknowns about associated headaches.
The Mini-Prevention Concept in Migraine Care: Deena Kuruvilla, MDJune 14th 2021
The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine
NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and OptimizationMay 19th 2021
The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.
Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhDMay 4th 2021
The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.